New data collected as part of an international clinical trial involving GMRF has found promising results of an anti-tumour medication in patients with advanced solid cancers.
The patients are participating in a study to explore the drug’s potential to selectively bolster cancer-fighting immune cells.
The new clinical data has shown that five of fourteen evaluable patients (36%) have achieved tumour control, indicating that their disease stabilised, despite their advanced stage of cancer.
These early signs of the potential clinical benefit of the treatment are positive as this trial aims to determine the recommended dose for the next trial phase.
The ongoing early phase clinical trial is being conducted through both national and international researchers, including Greenslopes Private Hospital. Led by Associate Professor Victoria Atkinson and coordinated by GMRF’s Clinical Trials Unit together with the nursing and pharmacy teams of the Cyril Gilbert Cancer Centre, the trial is sponsored by clinical stage immunotherapy company Medicenna.
Clinical Trials at GMRF
Our Clinical Trials Unit includes a team of specialist research nurses and scientists who provide our research partners with first-class conduct, management and coordination of multi-centre national and international clinical research trials. Patient-focussed care is at the heart of everything they do.
Read more about this trial
Read Medicenna’s press release about the new data